CytoDyn (CytoDyn) Forward Dividend Yield % : 0.00% (As of Jun. 06, 2024)

View and export this data going back to 2005. Start your Free Trial

What is CytoDyn Forward Dividend Yield %?

As of today (2024-06-06), the Forward Annual Dividend Yield of CytoDyn is 0.00%.

As of today (2024-06-06), the Trailing Annual Dividend Yield of CytoDyn is 0.00%.

CYDY's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.685
* Ranked among companies with meaningful Forward Dividend Yield % only.

CytoDyn's Dividends per Share for the three months ended in Feb. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of CytoDyn's Forward Dividend Yield %

For the Biotechnology subindustry, CytoDyn's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoDyn's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where CytoDyn's Forward Dividend Yield % falls into.

CytoDyn Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

CytoDyn (OTCPK:CYDY) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

CytoDyn Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of CytoDyn's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoDyn (CytoDyn) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

296:Germany

Address

1111 Main Street, Suite 660, Vancouver, WA, USA, 98660

Website

https://www.cytodyn.com

CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.

Executives

Tyler Blok	officer: EVP of Legal Affairs	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes	director
Ryan Dunlap	director	310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman	officer: President	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins	director	1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese	officer: Chief Financial Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor	officer: Chief Operating Officer	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland	officer: CFO, Treasurer and Secretary	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov	director	1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660